Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT

Affiliation auteurs!!!! Error affiliation !!!!
TitreHematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT
Type de publicationJournal Article
Year of Publication2019
AuteursRuggeri A, Labopin M, Savani B, Paviglianiti A, Blaise D, Volt F, Ciceri F, Bacigalupo A, Tischer J, Chevallier P, Koc Y, Cornelissen JJ, Ehninger G, Sanz G, Deconinck E, Rocha V, Baron F, Mohty M, Gluckman E, Nagler A
JournalBONE MARROW TRANSPLANTATION
Volume54
Pagination1987-1994
Date PublishedDEC
Type of ArticleArticle
ISSN0268-3369
Résumé

{Survival of patients with secondary acute myeloid leukemia (sAML) is poor. Cord blood transplantation (UCBT) and non-T-cell-depleted stem cell transplantation from haploidentical donors (HAPLO) are both strategies that have shown encouraging results in patients who do not have an human leukocyte antigen (HLA)-matched sibling or unrelated donor. We retrospectively analyzed outcomes of 409 adults with sAML receiving either UCBT (n = 163) or HAPLO (n = 246) in EBMT centers. Myelodysplastic syndrome (MDS) or myeloproliferative disorder (MPD) was the antecedent diagnosis in 79% of UCBT and 85% of HAPLO recipients. In multivariate analysis, UCBT was associated with higher risk of grade II-IV acute GVHD (HR 1.9
DOI10.1038/s41409-019-0582-5